Immune cell metabolic dysfunction in Parkinson’s disease.

Publication date: Mar 24, 2025

Parkinson’s disease (PD) is a multi-system disorder characterized histopathologically by degeneration of dopaminergic neurons in the substantia nigra pars compacta. While the etiology of PD remains multifactorial and complex, growing evidence suggests that cellular metabolic dysfunction is a critical driver of neuronal death. Defects in cellular metabolism related to energy production, oxidative stress, metabolic organelle health, and protein homeostasis have been reported in both neurons and immune cells in PD. We propose that these factors act synergistically in immune cells to drive aberrant inflammation in both the CNS and the periphery in PD, contributing to a hostile inflammatory environment which renders certain subsets of neurons vulnerable to degeneration. This review highlights the overlap between established neuronal metabolic deficits in PD with emerging findings in central and peripheral immune cells. By discussing the rapidly expanding literature on immunometabolic dysfunction in PD, we aim to draw attention to potential biomarkers and facilitate future development of immunomodulatory strategies to prevent or delay the progression of PD.

Open Access PDF

Concepts Keywords
Death Animals
Homeostasis Dopaminergic Neurons
Immunometabolic Humans
Parkinson Oxidative Stress
Rapidly Parkinson Disease

Semantics

Type Source Name
disease MESH Parkinson’s disease
disease MESH etiology
disease MESH death
disease MESH Defects
pathway REACTOME Metabolism
disease MESH stress metabolic
disease MESH inflammation
pathway REACTOME Reproduction
disease MESH neurodegenerative disorder
disease MESH tremor
disease MESH oxidative stress
pathway REACTOME Glycolysis
drug DRUGBANK Glutamic Acid
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK ATP
drug DRUGBANK NADH
pathway KEGG Oxidative phosphorylation
drug DRUGBANK Coenzyme M
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Isoxaflutole
disease MESH neuroblastoma
drug DRUGBANK Oxygen
drug DRUGBANK BV2
drug DRUGBANK L-Leucine
pathway REACTOME Immune System
disease MESH REM sleep behavior disorder
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH syndrome
disease MESH Mitochondrial dysfunction
drug DRUGBANK Flunarizine
pathway REACTOME Mitophagy
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH neuroinflammation
drug DRUGBANK Rotenone
drug DRUGBANK Capsaicin
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Potassium Chloride
disease MESH tic
drug DRUGBANK Levodopa
drug DRUGBANK Methylergometrine
drug DRUGBANK Calcium
drug DRUGBANK Cardiolipin
drug DRUGBANK Water
pathway REACTOME Autophagy
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Ilex paraguariensis leaf
pathway KEGG Lysosome
disease MESH shock
drug DRUGBANK Nitric Oxide
disease MESH frontotemporal dementia
disease MESH palsy
disease MESH astrogliosis
drug DRUGBANK Trestolone
drug DRUGBANK Dopamine
pathway KEGG Proteasome
drug DRUGBANK Spinosad
drug DRUGBANK Tretamine
pathway KEGG Carbon metabolism
pathway KEGG Parkinson disease
drug DRUGBANK Huperzine B
drug DRUGBANK Cysteamine
disease MESH hypoxia
drug DRUGBANK Carboxyamidotriazole
disease MESH atrophy
disease MESH Parkinsonism
drug DRUGBANK Meperidine
drug DRUGBANK Guanosine
drug DRUGBANK L-Cysteine
drug DRUGBANK Glutathione
drug DRUGBANK Ascorbic acid
pathway REACTOME Macroautophagy
drug DRUGBANK Angiotensin II
drug DRUGBANK Quercetin
disease MESH synucleinopathy
pathway REACTOME Apoptosis
pathway REACTOME Chaperone Mediated Autophagy
disease MESH neuron degeneration
drug DRUGBANK Troleandomycin
drug DRUGBANK Iron
drug DRUGBANK Risedronate
disease MESH dementia
disease MESH GBA deficiency
disease MESH MPTP induced parkinsonism
disease MESH Alzheimer’s disease
disease MESH frontotemporal Lobar degeneration
disease MESH amyotrophic lateral sclerosis
pathway KEGG Amyotrophic lateral sclerosis
drug DRUGBANK Serine
drug DRUGBANK Sulfasalazine
disease MESH multiple system atrophy
disease MESH progressive supranuclear palsy
disease MESH cancer
pathway KEGG Alzheimer disease

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *